title: Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
authors.affiliation: Department of Hematology, Karolinska University Hospital, Stockholm, Sweden anders.osterborg@karolinska.se.
authors.forename: Anders
authors.initials: A
authors.lastname: Österborg
authors.affiliation: GlaxoSmithKline, Research Triangle Park, NC, USA.
authors.forename: Roxanne C
authors.initials: RC
authors.lastname: Jewell
authors.affiliation: Cancer Therapy Research Center, San Antonio, TX, USA (formerly Roswell Park Cancer Institute, Buffalo, NY, USA).
authors.forename: Swami
authors.initials: S
authors.lastname: Padmanabhan-Iyer
authors.affiliation: UCSD Moores Cancer Center, La Jolla, CA, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Kipps
authors.affiliation: Faculty Hospital Brno, Dept of Internal Medicine/Hemato-Oncology, Czech Republic.
authors.forename: Jiří
authors.initials: J
authors.lastname: Mayer
authors.affiliation: Universitätsklinikum Ulm, Department of Internal Medicine III, Germany.
authors.forename: Stephan
authors.initials: S
authors.lastname: Stilgenbauer
authors.affiliation: Center for Clinical Haematology, Nottingham University Hospitals, UK.
authors.forename: Cathy D
authors.initials: CD
authors.lastname: Williams
authors.affiliation: Department of Hematology, Medical University of Gdansk, Poland.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Hellmann
authors.affiliation: Weill Cornell Medical College, Division of Hematology/Oncology, New York, NY, USA.
authors.forename: Richard R
authors.initials: RR
authors.lastname: Furman
authors.affiliation: Department of Hematology, Medical University of Lodz, Poland.
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Robak
authors.affiliation: St James' Institute of Oncology, St James' University Hospital, Leeds, UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Hillmen
authors.affiliation: First Faculty of Medicine, Charles University General Hospital, Prague, Czech Republic.
authors.forename: Marek
authors.initials: M
authors.lastname: Trnêný
authors.affiliation: The Ernest and Helen Scott Haematological Research Institute, University of Leicester, UK.
authors.forename: Martin J S
authors.initials: MJ
authors.lastname: Dyer
authors.affiliation: Klinika Hematologii CMUJ, Krakow, Poland.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Piotrowska
authors.affiliation: University Hospital Kralovske Vinohrady, Department of Clinical Hematology, Prague, Czech Republic.
authors.forename: Tomas
authors.initials: T
authors.lastname: Kozak
authors.affiliation: GlaxoSmithKline, Collegeville, PA, USA.
authors.forename: Ira V
authors.initials: IV
authors.lastname: Gupta
authors.affiliation: GlaxoSmithKline, Collegeville, PA, USA.
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Phillips
authors.affiliation: GlaxoSmithKline, Research Triangle Park, NC, USA.
authors.forename: Nancy
authors.initials: N
authors.lastname: Goldstein
authors.affiliation: GlaxoSmithKline, Research Triangle Park, NC, USA.
authors.forename: Herbert
authors.initials: H
authors.lastname: Struemper
authors.affiliation: Genmab, Copenhagen, Denmark.
authors.forename: Nedjad
authors.initials: N
authors.lastname: Losic
authors.affiliation: Genmab, Copenhagen, Denmark.
authors.forename: Steen
authors.initials: S
authors.lastname: Lisby
authors.affiliation: The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: William G
authors.initials: WG
authors.lastname: Wierda
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005500:Follow-Up Studies; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014740:Vidarabine; C527517:ofatumumab; C024352:fludarabine
keywords: fludarabine-refractory; ofatumumab; pivotal study